ONCY
- Oncolytics Biotech Inc.
()
Overview
Company Summary
Oncolytics Biotech Inc. is a biopharmaceutical company focused on the development and commercialization of oncolytic viruses as potential treatments for various types of cancer. Their primary focus is on using the body's own immune system to fight cancer by harnessing the power of viruses.
Oncolytic viruses are genetically modified viruses that are designed to selectively target and destroy cancer cells while leaving normal healthy cells unharmed. These viruses are engineered to replicate inside the tumor cells, causing their destruction and also stimulating an immune response. This unique approach has the potential to offer a more effective and less toxic alternative to traditional cancer treatments like chemotherapy and radiation.
The company's flagship product is REOLYSIN�, an oncolytic virus based on the common reovirus. REOLYSIN� is being investigated in various clinical trials for the treatment of solid tumors, such as ovarian, lung, pancreatic, and colorectal cancers, among others. The goal is to evaluate its safety, efficacy, and potential in combination with other therapies to improve patient outcomes.
Oncolytics Biotech also seeks to collaborate with other pharmaceutical companies, academic institutions, and research organizations to advance their scientific understanding of oncolytic viruses and explore potential applications in other types of cancer.
In summary, Oncolytics Biotech Inc. is dedicated to developing and commercializing oncolytic virus therapies that have the potential to revolutionize cancer treatment by leveraging the body's immune system to target and destroy cancer cells while sparing healthy cells.